By using high-affinity polypeptide monobody binders of human SHP2 and a nanobody recognizing human ASC protein conjugated to the CUL2 substrate receptor VHL, we achieve near-complete proteolysis of endogenous SHP2 and ASC in human cancer cell lines. Here, CUL2 is linked to cancer.